Merck Protillion Collaboration Sends MRK Soaring 15%
Can the Merck Protillion Collaboration really help MRK outrun its post-Keytruda patent fears and justify Wall Street’s sudden excitement?
Merck Keytruda Rivalry Surges as Ivonescimab Stumbles
Is the latest ivonescimab setback a temporary stumble or a turning point in the Merck Keytruda Rivalry for lung cancer dominance?
Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology bet?